Axsome Therapeutics, Inc.

NasdaqGM:AXSM 株式レポート

時価総額：US$3.8b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Axsome Therapeutics マネジメント

マネジメント 基準チェック /24

Axsome Therapeutics'の CEO はHerriot Tabuteauで、 Jan2012年に任命され、 の在任期間は 12.42年です。 の年間総報酬は$ 9.90Mで、 7.6%給与と92.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.015%を直接所有しており、その価値は$ 549.39K 。経営陣と取締役会の平均在任期間はそれぞれ5年と9.5年です。

主要情報

Herriot Tabuteau

最高経営責任者

US$9.9m

報酬総額

CEO給与比率7.6%
CEO在任期間12.4yrs
CEOの所有権0.02%
経営陣の平均在職期間5yrs
取締役会の平均在任期間9.5yrs

経営陣の近況

Recent updates

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

May 10

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09
Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Apr 13
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Mar 17
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges

Feb 21

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Dec 27
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Dec 12
Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Sep 12
Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Aug 08
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

May 13
Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 03
Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Mar 01
Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Nov 14
Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Axsome Therapeutics: Clear Path Ahead For AXS07

Oct 05

Axsome to resubmit marketing application for migraine therapy in Q3 2023

Sep 29

Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

Sep 16

Axsome begins enrolling in late-stage study of migraine drug AXS-07

Sep 01

Axsome gains 19% as FDA approves depression therapy

Aug 19

Axsome Therapeutics Q2 2022 Earnings Preview

Aug 08

Axsome: Breaking Bearish Trend

Jul 26

Axsome: One Step At A Time

Jul 01

Axsome And AXS-05: A Special Situation

May 02

Axsome: A Growth Transition

Apr 13

Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst

Apr 03

Axsome: A Biotech With Potential Approval Of Several Drugs In Coming Years

Mar 19

CEO報酬分析

Axsome Therapeutics の収益と比較して、Herriot Tabuteau の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$296m

Dec 31 2023US$10mUS$750k

-US$239m

Sep 30 2023n/an/a

-US$202m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$159m

Dec 31 2022US$8mUS$685k

-US$187m

Sep 30 2022n/an/a

-US$160m

Jun 30 2022n/an/a

-US$150m

Mar 31 2022n/an/a

-US$141m

Dec 31 2021US$8mUS$685k

-US$130m

Sep 30 2021n/an/a

-US$126m

Jun 30 2021n/an/a

-US$114m

Mar 31 2021n/an/a

-US$100m

Dec 31 2020US$7mUS$575k

-US$103m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$95m

Mar 31 2020n/an/a

-US$90m

Dec 31 2019US$5mUS$435k

-US$68m

Sep 30 2019n/an/a

-US$53m

Jun 30 2019n/an/a

-US$42m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$1mUS$435k

-US$31m

Sep 30 2018n/an/a

-US$29m

Jun 30 2018n/an/a

-US$27m

Mar 31 2018n/an/a

-US$26m

Dec 31 2017US$1mUS$435k

-US$29m

報酬と市場: Herriotの 総報酬 ($USD 9.90M ) は、 US市場 ($USD 6.83M ) の同規模の企業の平均を上回っています。

報酬と収益: Herriotの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Herriot Tabuteau (56 yo)

12.4yrs

在職期間

US$9,896,629

報酬

Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer, President and Chairman since January 2012. Dr. Tabuteau served as Interim Principal Fina...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Herriot Tabuteau
Founder12.4yrsUS$9.90m0.015%
$ 579.0k
Nick Pizzie
Chief Financial Officer6.1yrsUS$3.57m0.089%
$ 3.4m
Mark Jacobson
Chief Operating Officer8.7yrsUS$4.04m0.012%
$ 463.3k
Hunter Murdock
General Counsel & Secretary2.5yrsUS$3.06m0%
$ 0
Lori Englebert
Executive Vice President of Product Strategy3.8yrsデータなしデータなし
Ari Maizel
Executive VP & Head of Commercialless than a yearデータなしデータなし

5.0yrs

平均在職期間

46yo

平均年齢

経験豊富な経営陣: AXSMの経営陣は 経験豊富 であると考えられます ( 5年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Herriot Tabuteau
Founder12.4yrsUS$9.90m0.015%
$ 579.0k
Roger Jeffs
Independent Lead Director9.5yrsUS$400.34k0.35%
$ 13.4m
Mark Saad
Independent Director9.5yrsUS$405.34k0.022%
$ 825.1k
Susan Mahony
Independent Directorless than a yearUS$417.48k0%
$ 0
Mark Coleman
Independent Director9.5yrsUS$427.84k0.031%
$ 1.2m

9.5yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: AXSMの 取締役会 は 経験豊富 であると考えられます ( 9.5年の平均在任期間)。